173 related articles for article (PubMed ID: 31240995)
1. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China.
Huang K; Guo Y; Kang J; An L; Zheng Z; Ma L; Peng L; Wang H; Su R; Itoh Y; Wang C
Ther Adv Respir Dis; 2019; 13():1753466619853500. PubMed ID: 31240995
[TBL] [Abstract][Full Text] [Related]
2. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia.
Lee SD; Xie CM; Yunus F; Itoh Y; Ling X; Yu WC; Kiatboonsri S
Respirology; 2016 Jan; 21(1):119-27. PubMed ID: 26394882
[TBL] [Abstract][Full Text] [Related]
4. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
[TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
8. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
[TBL] [Abstract][Full Text] [Related]
9. Formoterol: a review of its use in chronic obstructive pulmonary disease.
Cheer SM; Scott LJ
Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
COPD; 2018; 15(4):334-340. PubMed ID: 30265816
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
13. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair
Yildiz P; Bayraktaroglu M; Gorgun D; Yuksel K
Clin Drug Investig; 2019 Oct; 39(10):991-1001. PubMed ID: 31332649
[TBL] [Abstract][Full Text] [Related]
16. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
17. Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow.
Huber B; Keller C; Jenkins M; Raza A; Aurivillius M
Ther Adv Respir Dis; 2022; 16():17534666221107312. PubMed ID: 35815354
[TBL] [Abstract][Full Text] [Related]
18. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
[TBL] [Abstract][Full Text] [Related]
20. The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases.
Bayiz H; Ozkaya S; Dirican A; Ece F
Drug Des Devel Ther; 2015; 9():5287-90. PubMed ID: 26451084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
